My Md Pharmaceuticals, Inc. MYMD
We take great care to ensure that the data presented and summarized in this overview for MyMD Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MYMD
Top Purchases
Top Sells
About MYMD
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Insider Transactions at MYMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 24
2023
|
Paul Rivard Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
150,000
+27.27%
|
$150,000
$1.11 P/Share
|
|
Aug 17
2023
|
Paul Rivard Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+9.09%
|
$25,000
$1.12 P/Share
|
|
Dec 08
2022
|
Paul Rivard Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+4.26%
|
$10,000
$1.53 P/Share
|
|
Nov 26
2021
|
Joshua Silverman Director |
BUY
Open market or private purchase
|
Direct |
5,000
+5.33%
|
$35,000
$7.55 P/Share
|
|
Nov 24
2021
|
Joshua Silverman Director |
BUY
Open market or private purchase
|
Direct |
10,000
+5.74%
|
$60,000
$6.7 P/Share
|
|
Nov 23
2021
|
Paul Rivard Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+6.52%
|
$90,000
$6.03 P/Share
|
|
Apr 16
2021
|
Christopher C Chapman Jr President, Chief Med. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,475
+50.0%
|
-
|
|
Apr 16
2021
|
Christopher C Schreiber Director |
SELL
Payment of exercise price or tax liability
|
Direct |
46,113
-34.32%
|
$184,452
$4.94 P/Share
|
|
Apr 16
2021
|
Christopher C Schreiber Director |
BUY
Exercise of conversion of derivative security
|
Direct |
131,750
+49.51%
|
-
|
|
Apr 16
2021
|
Billy Joe White Director |
SELL
Payment of exercise price or tax liability
|
Direct |
38,325
-35.0%
|
$153,300
$4.94 P/Share
|
|
Apr 16
2021
|
Billy Joe White Director |
BUY
Exercise of conversion of derivative security
|
Direct |
109,500
+49.41%
|
-
|
|
Apr 16
2021
|
Joshua Silverman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
38,325
-35.0%
|
$153,300
$4.94 P/Share
|
|
Apr 16
2021
|
Joshua Silverman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
109,500
+49.41%
|
-
|
|
Apr 16
2021
|
Robert C Schroeder Director |
SELL
Payment of exercise price or tax liability
|
Direct |
14,694
-33.45%
|
$58,776
$4.94 P/Share
|
|
Apr 16
2021
|
Robert C Schroeder Director |
BUY
Exercise of conversion of derivative security
|
Direct |
43,930
+50.0%
|
-
|
|
Feb 28
2020
|
Hudson Bay Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
638
-0.26%
|
$1,276
$2.81 P/Share
|
|
Feb 27
2020
|
Hudson Bay Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,300
-5.97%
|
$30,600
$2.72 P/Share
|
|
Feb 25
2020
|
Hudson Bay Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,000
-4.83%
|
$26,000
$2.92 P/Share
|
|
Dec 20
2019
|
Hudson Bay Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,000
+2.89%
|
$24,000
$3.02 P/Share
|
|
Dec 19
2019
|
Hudson Bay Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,700
+1.02%
|
$8,100
$3.08 P/Share
|